Journal
LEUKEMIA & LYMPHOMA
Volume 59, Issue 7, Pages 1634-1643Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2017.1397661
Keywords
Adult acute lymphoblastic leukemia; Escherichia coli asparaginase; native; pegylated; efficacy; toxicity
Categories
Funding
- Fondo de Investigaciones Sanitarias [PI10/01417]
- RTICC, Instituto de Salud Carlos III [RD12/0036/0029]
- CERCA Program, Generalitat de Catalunya, Spain [2014 SGR225(GRE)]
- 'La Caixa' Foundation
Ask authors/readers for more resources
Native or pegylated (PEG) asparaginase (ASP) are commonly used in treatment of acute lymphoblastic leukemia (ALL), but have been scarcely compared in the same trial in adult patients. Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL. Ninety-one patients received native ASP and 35 PEG-ASP in induction. No significant differences were observed in complete remission, minimal residual disease levels after induction and after consolidation, disease-free survival, and overall survival. No significant differences in grades 3-4 toxicity were observed in the induction period, although a trend for higher hepatic toxicity was observed in patients receiving PEG-ASP. In this trial the type of ASP did not influence patient response and outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available